Aterola

Aterola is a biotechnology company focused on developing innovative therapeutic vaccines for the treatment and prevention of atherosclerosis and related cardiovascular diseases. The company's lead research centers on targeting specific epitopes of Apolipoprotein B-100 to modulate the immune response and reduce the formation of arterial plaques. By leveraging peptide-based vaccine technology, Aterola aims to provide a long-term solution for managing cholesterol and vascular health beyond traditional statin therapy. The company is currently in the pre-clinical stage, advancing its candidates through foundational research and early-stage validation.